Just eight days after receiving a single dose of psilocybin, participants in a clinical trial showed noticeable improvements in their mood—a finding that points toward a radically faster treatment for one of the world's most pressing mental health challenges. The study, published in JAMA Network Open, involved 35 people with recurring depression who were randomly assigned to receive either psilocybin or a placebo (vitamin B3). Both groups received psychological support before, during, and after dosing. By the end of the six-week follow-up period, more than half of the psilocybin group no longer met the diagnostic criteria for depression, compared to just one person in the placebo group.
What makes this research distinctly valuable is its focus on something often overlooked in psychedelic medicine: whether psilocybin could help people with common, everyday depression—not only those whose symptoms have resisted all other treatments. Depression affects hundreds of millions worldwide, and most people living with it have never tried psychedelic therapy. For them, a fast-acting treatment that offers months of relief could reshape their relationship with their own recovery.
The benefits in the psilocybin group persisted for just over three months on self-rated outcomes before gradually diminishing. When the researchers followed participants for a full year, they observed that the gap between the two groups began to narrow as the placebo group also improved—a pattern the researchers note is entirely consistent with how depression naturally fluctuates over time. About a third of participants in both groups began antidepressant medication roughly four months into the trial, reflecting the real-world complexity of treating depression.
The treatment was generally well tolerated, though two participants experienced anxiety lasting several weeks—a reminder that even promising therapies carry risks.
Yet the researchers are refreshingly candid about a central methodological challenge: the impossibility of truly blinding participants in psilocybin studies. Despite using identical capsules and an active placebo, almost all participants correctly guessed which treatment they received. Psilocybin produces a distinctive altered state that cannot be hidden. This matters because expectations shape outcomes. Those who received psilocybin experienced powerful effects that may have amplified their hopes for recovery, while those in the placebo group felt nothing and potentially experienced disappointment. Neither response is neutral when people later rate their own moods.
The researchers point out that placebo groups in psilocybin trials often show less improvement than placebo groups in traditional antidepressant studies—a pattern they observed here as well. This creates a risk that the drug's true effects could appear larger than they actually are. Answering this question—how much of psilocybin's benefit comes from the substance itself versus the powerful experience and expectation surrounding it—will be crucial for understanding its real place in future mental health care.
Still, the study adds meaningful evidence to a growing body of research suggesting that psilocybin may offer a fast-acting, relatively long-lasting treatment for depression in people beyond just those with treatment-resistant forms. For a field searching for better options, these qualities could indeed make a real difference.